Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31131353 | 0.88 | MAOA (0.84) | MAOACA12CA1CA2CA9 | |
| SCHEMBL19446666 | 0.88 | MAOA (0.84) | MAOACA12CA1CA2CA9 | |
| SCHEMBL29394565 | 0.88 | MAOA (0.84) | MAOACA12CA1CA2CA9 | |
| SCHEMBL29561461 | 0.88 | MAOA (0.84) | MAOACA12CA1CA2CA9 | |
| SCHEMBL311194 | 0.88 | MAOA (0.84) | MAOACA12CA1CA2CA9 | |
| SCHEMBL6689378 | 0.86 | CYP17A1 (0.51) | MAOACA12CA1CA2CA9 | |
| SCHEMBL19446605 | 0.85 | MAOA (0.80) | MAOACA12CA1CA2CA9 | |
| SCHEMBL9292677 | 0.84 | MAOA (0.62) | MAOACA12CA1CA2CA9 | |
| SCHEMBL250353 | 0.83 | MAOA (0.76) | MAOACA12CA1CA2CA9 | |
| SCHEMBL22104536 | 0.83 | MAOA (0.95) | MAOACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058312-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230058312-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2023-02-23 | — | — | US | disclosed |
| CN-115397806-A | Aryl and heteroaryl compounds and their therapeutic use in conditions associated with altered activity of galactocerebrosidase | 增益治疗股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-4065546-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | Gain Therapeutics SA (CH) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021105906-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105906-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2021-06-03 | — | — | WO | disclosed |
| US-7951814-B2 | Quinazolinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-05-31 | — | — | US | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
| WO-2009118596-A2 | PHTHALIMIDE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-10-01 | — | — | WO | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-4990663-A | Mixing 3,4-dichloroaniline with an amine compound to improve storage stability and minimize dechlorination | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-02-05 | — | — | US | disclosed |
| EP-0398542-A2 | Process for preparing 3,4-dichloroaniline | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058312-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GBA1, GALC, MAN2B1 | MAOA 171/4885CA12 3143/4885CA1 3809/4885 |
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | MAOA 3805/4885CA12 4053/4885CA1 4451/4885 |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPC3 | MAOA 2168/4885CA12 4811/4885CA1 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.